Clinical trials: HIV Disease
HIV Infections
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States.
- Trial name
- PROPEL (NCT07473778)
- Testing
- Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF)
- Where
- 44 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Gilead Sciences
Diarrhea, HIV Infections
A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea
To determine the efficacy and safety of Sandostatin (octreotide) compared to placebo in controlling diarrhea which is a manifestation or complication of documented HIV infection and which is refractory (does not respond) to all…
- Trial name
- NCT00002252
- Testing
- Octreotide
- Where
- 23 sites in United States
- Sponsor
- Sandoz
HIV-1 Infection
Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults
The primary objective of this study is to evaluate the non-inferiority of switching to emtricitabine/rilpivirine/tenofovir alafenamide (FTC/RPV/TAF) fixed dose combination (FDC) as compared to continuing the non-nucleoside…
- Trial name
- NCT02345226
- Testing
- FTC/RPV/TAF, EFV/FTC/TDF
- Where
- 117 sites in United States, Belgium and 7 more
- Volunteers
- 881 people
- Sponsor
- Gilead Sciences
HIV Infections
Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (< 50 copies/mL) (c/mL) at 48 weeks (W48) Main Secondary objectives: Comparison of the two arms for genotypic…
- Trial name
- COOL (NCT00643968)
- Testing
- EFV+TDF, EFV+3TC+TDF
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
HIV Infections, HIV-1
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible…
- Trial name
- NCT00980538
- Testing
- Etravirine
- Where
- 29 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Janssen Sciences Ireland UC
Chronic Hepatitis B
Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)
This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.
- Trial name
- NCT00140725
- Testing
- Lamivudine plus Polyethylene glyco-interferon alfa-2b, Lamivudine
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus
A Trial to Assess the Functionality of Female Condom With a Silicone Elastomer Vaginal Ring
A multi-center, open-label, randomized, two-period, crossover non-inferiority trial to assess the functionality of female condoms with a silicone elastomer vaginal ring.
- Trial name
- NCT01755754
- Testing
- Silicone Elastomer Vaginal Ring, Female Condom
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Acquired Immunodeficiency Syndrome, Anemia
A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) Therapy
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa in AIDS patients for the treatment of anemia that is a result of the disease and zidovudine (AZT) treatment.
- Trial name
- NCT00270283
- Testing
- epoetin alfa
- Volunteers
- 102 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
HIV Infections
ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.
This 2 arm study will assess the immunological benefits of adding Fuzeon to an antiretroviral regimen in HIV-infected, Fuzeon-naive patients with a CD4 cell count <250 cells/mm3 and an HIV RNA viral load <400 copies/mL.
- Trial name
- NCT00461266
- Testing
- enfuvirtide [Fuzeon], Antiretroviral therapy
- Where
- 7 sites in Australia
- Sponsor
- Hoffmann-La Roche
HIV Infections
WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.
The purpose of this study is to evaluate the tolerability of a subcutaneous needle-free injection device used to administer Fuzeon, compared with the standard needle/syringe supplied with commercial Fuzeon.
- Trial name
- NCT00233883
- Testing
- enfuvirtide [Fuzeon]
- Where
- 17 sites in United States
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
HIV
Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1
The purpose of this study is to evaluate the safety and tolerability of VAC-3S in controlled HIV patients receiving standard of care antiretroviral treatment.
- Trial name
- NCT02390466
- Testing
- VAC-3S
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- InnaVirVax
HIV
An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy
To test the hypothesis that AGT103-T cells therapy will allow HIV positive individual to reduce, modify or eliminate antiretroviral therapy.
- Trial name
- NCT05540964
- Testing
- Antiretroviral Therapy Interruption(ATI)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- American Gene Technologies International Inc.
Meningitis, Cryptococcal, HIV Infections
The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis
To evaluate the safety of escalating doses of RMP-7 administered in persons with HIV infection and cryptococcal meningitis and to determine the MTD of the drug.
- Trial name
- NCT00002316
- Testing
- Lobradimil, Amphotericin B
- Where
- 11 sites in United States
- Sponsor
- Alkermes, Inc.
Human Immunodeficiency Virus
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was…
- Trial name
- NCT02919306
- Testing
- Ad26.Mos.HIV, MVA-Mosaic
- Where
- Thailand
- Volunteers
- 27 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
Candidiasis, Esophageal, HIV Infections
A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis
The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.
- Trial name
- NCT00005921
- Testing
- L-743,872
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV
A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials
The purpose of this study was primarily to assess the long-term safety and tolerability of TMC114/rtv in addition to an individually optimized background antiretroviral therapy in HIV-1 infected participants.
- Trial name
- NCT02187107
- Testing
- TMC114, rtv
- Where
- 11 sites in Australia, Austria and 6 more
- Volunteers
- 52 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections, Hepatitis C
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC)…
- Conditions
- HIV Infections, Hepatitis C, HCV Infection
- Trial name
- NCT00959699
- Testing
- PegIFN-2b, RBV, Boceprevir
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
VioOne HIV Profile Supplemental Assay
Assessment of the sensitivity, specificity and reproducibility of the VioOne HIV Profile Supplemental Assay
- Trial name
- NCT03727932
- Testing
- VioOne HIV Profile Supplemental Assay
- Where
- United States
- Volunteers
- 757 people
- Sponsor
- Avioq, Inc.
HIV Infections
Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
The purpose of this study is to test 2 different dosing regimens of GW433908/ritonavir (RTV) versus lopinavir (LPV)/RTV when each is given with 2 active reverse transcriptase inhibitors (RTIs), in patients who have taken anti-HIV…
- Trial name
- NCT00025727
- Testing
- Lopinavir/Ritonavir, Ritonavir, GW433908
- Where
- 32 sites in United States
- Volunteers
- 330 people
- Sponsor
- GlaxoSmithKline
HIV Infections, Lipodystrophy
A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
The purpose of this study is to see if the findings of increased lactic acid and abnormal fat distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or Combivir (a pill containing lamivudine plus…
- Trial name
- NCT00005764
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
- Where
- 31 sites in United States
- Volunteers
- 100 people
- Sponsor
- Glaxo Wellcome
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.